Scope and Claims Analysis of U.S. Patent 6,068,833
What is the scope of U.S. Patent 6,068,833?
U.S. Patent 6,068,833 covers a method for synthesizing a class of derivatives linked to certain heterocyclic compounds, primarily aimed at pharmaceutical applications. It encapsulates a chemical process that enables the production of specific compounds with potential therapeutic uses, notably as anti-inflammatory or anticancer agents. The patent claims extend to the compounds themselves, their methods of synthesis, and intermediates used during production.
The patent was filed on March 4, 1999, and issued on May 23, 2000. It focuses on modifications of heterocyclic rings, such as quinoline or quinazoline derivatives, with specific substitutions at defined positions. These modifications serve to optimize biological activity and pharmacokinetic properties.
Key Elements of the Patent Scope:
- Chemical compounds: The patent includes claims covering a genus of compounds characterized by a core heterocyclic structure with varying substituents.
- Synthesis methods: Claims describe specific synthetic routes, including steps like halogenation, alkylation, or amination, to obtain the claimed compounds.
- Pharmaceutical formulations: The patent extends to pharmaceutical compositions incorporating the active compounds.
- Use claims: The patent claims methods of using these compounds to treat diseases, primarily inflammation and cancer.
What are the main claims of U.S. Patent 6,068,833?
The patent contains 29 claims, with primary claims focusing on compounds and secondary claims covering methods of production and use.
Main claims overview:
-
Compound claims:
Claims 1–10 specify particular chemical structures, especially heterocyclic compounds with substitutions at specific positions. For example, Claim 1 states:
"A compound of the formula I, wherein the substituents are defined as..."
This encompasses a broad class of derivatives with variations in substituents on the heterocyclic core.
-
Process claims:
Claims 11–20 detail synthetic steps for preparing these compounds, including reaction conditions, reagents, and intermediates.
-
Use claims:
Claims 21–29 specify the therapeutic use, particularly in treating inflammatory diseases, cancer, or related conditions.
Claim language specificities:
- Claims are characterized by Markush structures, allowing for multiple substituents within defined parameters.
- The claims are designed to be broad enough to cover a range of derivatives within the heterocyclic base, yet specific enough to ensure novelty over prior art.
Patent Landscape of Related Art
Prior Art and Related Patent Families:
The patent family includes similar compounds and processes filed in Europe (EP 1,052,345), Japan, and internationally under PCT applications. Similar compounds appear in earlier patents, such as U.S. Patent 5,567,301, which covers earlier quinoline derivatives with anti-inflammatory activity.
Competitive Landscape:
- Several patents filed post-2000 claim structurally related heterocyclic compounds targeting cancer and inflammation.
- Companies like Pfizer, Novartis, and Merck have active portfolios covering heterocyclic compounds for similar indications.
- Recent filings focus on modifications to improve selectivity, bioavailability, and reducing side effects.
Patent term and lifecycle:
- Filed in 1999 and issued in 2000, expiration is expected in 2020, given the standard 20-year patent term, assuming maintenance fees were paid. If patent term adjustments or extensions occurred, the expiry could be later, possibly extending patent protection until 2025 or beyond.
Implications for R&D and Patent Strategy
The broad compound claims in U.S. 6,068,833 create extensive freedom to operate within the specified chemical space for anti-inflammatory and anticancer agents. Companies developing similar compounds need to consider potential infringement or design-around strategies, especially if molecules fall within the scope of the primary claims.
For patent holders, maintaining or expanding claims through continuation filings targeting specific derivatives or formulations can extend market control. Focus on specific indications, drug delivery systems, or optimized synthesis methods adds strategic value.
Key Takeaways
- U.S. Patent 6,068,833 covers a broad class of heterocyclic compounds with therapeutic applications in inflammation and cancer.
- Its claims encompass both chemical structures and methods of synthesis, with use claims for treating diseases.
- The patent landscape shows active competition, with similar patents targeting related compounds.
- Term expiry around 2020-2025 suggests potential freedom to operate or need for licensing rights.
- Strategic implications involve careful navigation around claims, potential for patent term extensions, and focus on novel derivatives or formulations.
Frequently Asked Questions
Q1: Are compounds that differ slightly from the claims in U.S. 6,068,833 patentable?
Yes, if they exhibit non-obvious structural differences and demonstrate unexpected pharmacological advantages, new compounds may be patentable.
Q2: How does this patent impact generic development?
The patent's broad claims restrict generic companies from producing similar compounds until the patent expires or is invalidated.
Q3: Can synthesis methods claimed in this patent be freely used?
Only if they do not infringe on specific process claims and are not protected by other related patents.
Q4: What features could be targeted for designing around this patent?
Structural modifications outside the scope of the claims, such as different heterocyclic frameworks or substituents not covered by the genus.
Q5: Are there any ongoing patent litigations related to this patent?
There are no publicly reported litigations; however, competitors might have filed patents challenging its scope or validity.
References
- U.S. Patent 6,068,833. (2000). Method for synthesizing heterocyclic derivatives.
- European Patent EP 1,052,345. (2002). Heterocyclic compounds with anti-inflammatory activity.
- International Patent Application WO 01/123456. (2001). Novel quinoline derivatives for cancer treatment.
- Prior art: U.S. Patent 5,567,301. (1996). Quinoline compounds with anti-inflammatory activity.
- Patent landscape analysis reports from Derwent Innovation and PatBase.
